Table 2.

Transplant outcomes of all patients (n = 145)

Outcome	Results
Neutrophil engraftment time (days), median (range)	13 (10–21)
Platelet engraftment time (days), median (range)	17 (9–108)
Cumulative incidence of acute GVHD (%), mean ± SD
None	41.1 ± 7.2
Grade I	24.6 ± 4.9
Grade II	23.4 ± 4.5
Grade III	6.8 ± 3.1
Grade IV	4.1 ± 1.0
Cumulative incidence of chronic GVHD (%), mean ± SD
None	53.0 ± 4.6
Mild	24.5 ± 2.8
Moderate	10.0 ± 3.7
Severe	12.5 ± 3.4
Cumulative incidence of TRM (%), mean ± SD	8.2 ± 2.8
4-year CIR (%), mean ± SD	21.3 ± 5.6
4-year LFS (%), mean ± SD	70.5 ± 8.2
4-year OS (%), mean ± SD	78.6 ± 9.0

GVHD: Graft-versus-host disease; TRM: Transplant-related mortality; CIR: Cumulative incidence of relapse; LFS: Leukemia-free survival; OS: Overall survival; SD: Standard deviation.